JOSÉ LUIS
CABRIADA NUÑO
Chercheur jusqu' 2022
Hospital Universitario de Basurto
Bilbao, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario de Basurto (29)
2024
-
Environmental Exposure to Trace Elements and Heavy Metals Preceding the Clinical Onset of Inflammatory Bowel Disease
Crohn's and Colitis 360, Vol. 6, Núm. 1
-
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612
-
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Pharmaceutics, Vol. 16, Núm. 5
2023
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
-
Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease
United European Gastroenterology Journal, Vol. 11, Núm. 1, pp. 9-18
2022
-
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)
Journal of Clinical Medicine
-
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU
Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
2021
-
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry
Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97
-
Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study
Journal of Clinical Medicine, Vol. 10, Núm. 13
2020
-
Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain)
Gastroenterology, Vol. 159, Núm. 2, pp. 781-783
-
Early microscopic findings in preclinical inflammatory bowel disease
Digestive and Liver Disease, Vol. 52, Núm. 12, pp. 1467-1472
2019
-
Immunosuppression for inflammatory bowel disease does not influence Epstein–Barr viral load in the short-term
Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 542-547
-
The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?
Journal of Clinical Apheresis, Vol. 34, Núm. 6, pp. 680-685
2018
-
Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors
Digestive and Liver Disease, Vol. 50, Núm. 8, pp. 812-819
-
Characteristics and Progression of Preclinical Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1459-1466
-
New psychometric data from the Spanish versions of the Glasgow Dyspepsia Severity Score and the Dyspepsia-Related Health Scale measures
Revista Española de Enfermedades Digestivas, Vol. 110, Núm. 1, pp. 10-18
-
New psychometric data from the Spanish versions of the glasgow dyspepsia severity score and the dyspepsia-related health scale measures
Revista Espanola de Enfermedades Digestivas, Vol. 110, Núm. 1, pp. 10-18
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402